Caribou Biosciences, Inc.
Caribou Biosciences, Inc. (CRBU): 7 pipeline candidates · ~13 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
12.7 months
D/E 0.46 · 0% dilution
Lead: Approved
7 candidates
N/A
0 buys · 5 sells (180d)
A transparent, data-derived signal for Caribou Biosciences, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$167.6M
Cash
$12.1M
Quarterly Burn
$27.0M
Runway
12.7 mo
Revenue
$2.4M
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (7 candidates)
| Drug | Phase |
|---|---|
| caribou-sponsored investigational therapy | — |
| CB-010 | Phase 1 |
| CB-011 | Phase 1 |
| CB-012 | Phase 1 |
| CB-020 | — |
| vispa-cel | Phase 1 |
| vispa-cel based on fda interactions to date | Approved |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
131
Total value held
$60.0M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 7,534,456 | $14.3M |
| renaissance technologies llc | 2,590,497 | $4.9M |
| blackrock, inc. | 2,143,085 | $4.1M |
| two sigma investments, lp | 1,759,934 | $3.3M |
| bank of america corp /de/ | 1,297,167 | $2.5M |
| marshall wace, llp | 1,205,668 | $2.3M |
| millennium management llc | 1,074,421 | $2.0M |
| susquehanna international group, llp | 1,047,203 | $2.0M |
| geode capital management, llc | 1,017,959 | $1.9M |
| pfm health sciences, lp | 957,787 | $1.8M |
Showing top 10 of 131 institutional holders of Caribou Biosciences, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Caribou Biosciences, Inc.'s pipeline?
Caribou Biosciences, Inc. (CRBU) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Caribou Biosciences, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Caribou Biosciences, Inc. has approximately 12.7 months of cash runway.
What is Caribou Biosciences, Inc.'s market capitalization?
Caribou Biosciences, Inc.'s market capitalization is approximately $167.6M.
Who is the CEO of Caribou Biosciences, Inc.?
Dr. Rachel E. Haurwitz Ph.D. is the chief executive officer of Caribou Biosciences, Inc. (CRBU).
Get the full picture on Caribou Biosciences, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.